Please assess the completion status of the following clinical trial:

Trial Title: LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* A clinical diagnosis of psoriasis vulgaris for at least 6 months involving the trunk and/or limbs, amenable to treatment with maximum of 100 g of trial medication per week~* Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) involving 2-30% of the body surface area (BSA)~* A target lesion/target location of at least 3 cm at its longest axis located on the body (i.e., not on the scalp, face or intertriginous areas), scoring at least 1 ('mild') for each of redness, thickness and scaliness, and at least 4 in total by the Investigator's Assessment of Severity of the Target Lesion/Location~For subjects participating in hypothalamic-pituitary-adrenal (HPA)-axis testing, furthermore:~* An extent of psoriasis vulgaris on trunk and/or limbs of disease severity (PGA) of at least 'moderate' affecting between 10 and 30% of the body surface area (BSA) excluding psoriatic lesions of genitals and skin folds at Visit 1.~EXCLUSION CRITERIA:~* Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to Visit 1:~  * etanercept - within 4 weeks prior to Visit 1~ * adalimumab, infliximab - within 8 weeks prior to Visit 1~ * ustekinumab - within 16 weeks prior to Visit 1~ * secukinumab - within 12 weeks prior to Visit 1~ * other products - within 4 weeks/5 half-lives prior to Visit 1 (whichever is longer)~* Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g. corticosteroids, retinoids, methotrexate, ciclosporin and other immunosuppressants) within 4 weeks prior to Visit 1~* Systemic treatment with apremilast within 4 weeks prior to Visit 1~* Psoralen combined with Ultraviolet A (PUVA) therapy within 4 weeks prior to Visit 1~* Ultraviolet B (UVB) therapy within 2 weeks prior to Visit 1~* Severe and/or extensive scalp psoriasis which, in the opinion of the investigator, requires treatment with potent or super-potent corticosteroids which will be prohibited during the trial~For subjects participating in HPA-axis testing, furthermore:~* Antidepressive medications within 4 weeks prior to Visit 1 or during the trial. Oestrogen therapy (including contraceptives), antidepressant medications and any other medication known to affect cortisol levels or HPA axis integrity within 4 weeks prior to baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LEO 90100 aerosol foam (Type: ACTIVE_COMPARATOR): Topical application twice weekly for 52 weeks
- LEO 90100 aerosol foam vehicle (Type: PLACEBO_COMPARATOR): Topical application twice weekly for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete